Figure 3. The RNA or protein expression changes of lung cancer cells with lnc-BMPl-1 over-expression vs. NC cells, the CSE vs. DMSO treated 16HBE cells, and 5-AzaC or TSA treatment. (A) The protein expression of Bcl-2, Cav-1 and DNMT3a in different lung cancer cell lines with lnc-BMP1-1 over-expression vs. NC cells; the protein expression were detected using western blotting analyses, protein expression was normalized against GAPDH or α-tubulin protein; the value above each band indicates the fold change of protein expression relative to their control; (B) The cell viability of CSE (vs. DMSO) treated 16HBE cells at 5th passage; (C) The cell viability of CSE (vs. DMSO) treated 16HBE cells at 10th passage; (D) The expression of lnc-BMP1-1, Cav-1 were reduced in CSE treated 16HBE cells both in 5th and 10th passage, and made greater decline in 10th than in 5th passage (the same gene was compared in 5th and 10th generation of CSE treated 16HBE cells, #P<0.05, ##P<0.01). The mRNA expression of Cav-1 in A549-BMP vs. A549-NC (E), GLC82-BMP vs. GLC82-NC(F), respectively; In A549 cells treated with TSA, the expression of lnc-BMP1-1 (G) and Cav-7 (H) were increased, while DNMT3a (I) was decreased; The protein expression of HDAC2 (J) was decreased in A549-BMP cells. Data are represented as means ± SD. *P< 0.05, **P<0.01.